Home About Clinicians Patients Investors Careers Media Contact About > Senior Leadership Team Kevin R. Smith CEO Experience and Expertise Kevin combines more than 20 years of sales and marketing experience in the medical device industry with the keen instincts of an entrepreneur. He excels at leading cross functional teams and identifying opportunities for accelerated growth, both upstream and downstream. Prior to his appointment to CEO, Kevin was Executive Vice President of Sales & Marketing, Americas, leading Sirtex's business development initiatives while implementing a commercial strategy for profitable growth and LATAM expansion. Before joining Sirtex in 2017, Kevin was Executive Vice President of Business Development at Gel-e, Inc., a startup company based at the University of Maryland specializing in advanced material hemostasis products. His previous positions include Chief Commercial Officer of Sensium Healthcare along with Global Vice President of Sales & Marketing at Teleflex, where he was the senior sales and marketing executive in the company's $85 million cardiac business unit. Kevin holds a Master of Business Administration in Global Management from the University of Phoenix and a Bachelor of Science in Marketing from the University of Kentucky. Kevin R. Smith CEO Paul Andreassi Executive Vice President of Global Quality Assurance Jesse Hansen Global Head of Marketing Francis Jannot Executive Vice President of International Sales Cathleen Lowndes Chief Human Resources Officer Amy Pan Chief Financial Officer Suki Shergill Executive Vice President, Global Pricing & Market Access Kevin P. Smith General Counsel & Executive Vice President, Business Development Grant Spindler Global Head of Operations MaryLou Stroumbos Executive Vice President, Regulatory Affairs Mark Turco Global Chief Medical Officer & Executive Vice President of Research & Development Mission and Values Senior Leadership Team Who we are Sirtex Medical is a global healthcare business with offices in the U.S., Australia, Germany and Singapore, working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres. What are SIR-Spheres® Y-90 resin microspheres? SIR-Spheres® Y-90 resin microspheres are a medical device used in Selective Internal Radiation Therapy (SIRT) for treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy. To view the Technical Bulletin regarding our indication, click here. Contact or follow us Contact Us SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd. Terms of Use | Privacy Information W9-E-0214 Effective May 7, 2021, SIR-Spheres will have the following indication for use: SIR-Spheres Y-90 resin microspheres are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy. Click here to view our Technical Bulletin. Ok